Wednesday, June 7 | 8:30 a.m. – 5 p.m. ET | Washington, D.C. & Online
On June 7, the Roundtable on Genomics and Precision Health at the National Academy of Sciences will host a hybrid public workshop examining the use of DNA sequencing as a supplement to traditional newborn screenings for treatable, but not yet clinically evident, conditions. The workshop will feature family, patient advocate, and public health representative perspectives on the need for and readiness of newborn DNA sequencing and will explore potential impacts and risks.

Objectives:

• Examine the known and expected benefits, and potential harms, of the widespread utilization of newborn DNA sequencing
• Explore ethical as well as data security and ownership concerns associated with newborn DNA sequencing
• Address issues of next-generation newborn screening equity in the U.S.

Seating is limited for in-person attendees and registration is required. To learn more about the workshop, please visit the project webpage.